Healthcare Industry News: GnRH antagonist
News Release - November 12, 2008
Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business UnitPARSIPPANY, N.J., Nov. 12 -- (Healthcare Sales & Marketing Network) -- Ferring Pharmaceuticals Inc. announces the promotion of William N. Garbarini, Jr. to Vice President of its new Orthopaedics and Urology Business Unit, recently formed by merging these clinical product areas. Garbarini was formerly Executive Director of Ferring's Orthopaedics Business Unit.
In his new role, Garbarini is responsible for Ferring's two marketed products in these areas, euflexxa® (1% sodium hyaluronate) for the pain caused by knee osteoarthritis, and PROSED® DS for the relief of discomfort of the lower urinary tract. He will also oversee the U.S. sales and marketing of Ferring's pipeline of urology products, including a GnRH antagonist for prostate cancer.
"Bill's exceptional talent, leadership and wealth of experience in pharmaceutical marketing have driven his rapid rise and recognition in the health care industry," said Wayne Anderson, President of Ferring. "After spearheading the growth of our infertility and orthopaedics businesses, he is extremely qualified to lead our new Orthopaedics and Urology unit."
During his tenure, Garbarini directed the launches of three key products in the Ferring portfolio. After joining Ferring in 2001 as a Product Director for its infertility franchise, he launched BRAVELLE®, a highly purified, human-derived follicle-stimulating hormone (hFSH) for infertility treatment. Ferring quickly became a formidable player in the market and grew to become the leader in total infertility prescriptions.
Garbarini was soon promoted to the unit's Director of Marketing and oversaw the launch of MENOPUR® (menotropins for injection, USP), a purified human menopausal gonadotropin (hMG) for patients undergoing in vitro fertilization (IVF). The product grew Ferring's hMG segment and continued the Company's dominance in total infertility prescriptions.
In 2005, Garbarini became Senior Director of Marketing for Ferring's new Orthopaedic Business Unit, which further diversified Ferring's portfolio. He launched euflexxa® for the pain caused by knee osteoarthritis. Soon it became the fastest-growing product in Ferring's line. In 2006, he accepted further responsibility as the Executive Director of Sales and Marketing for the business unit.
Prior to joining Ferring, Garbarini was Director, Client Services for Caresoft, Inc. Previously, he served in various positions at Schering-Plough Corporation/Key Pharmaceuticals, Lowe McAdams Healthcare advertising agency, and Glaxo Wellcome, where he was honored as a top sales representative. Garbarini holds a B.S. degree in economics from the College of New Jersey and an M.B.A. degree in pharmaceutical management from Fairleigh Dickinson University, where he was granted membership in the Delta Mu Delta Honor Society.
About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring's line of products includes: EUFLEXXA® (hyaluronic acid) for pain from osteoarthritis in the knee; BRAVELLE® (urofollitropin for injection, purified); MENOPUR® (menotropins for injection, USP); REPRONEX® (menotropins for injection, USP); NOVAREL® (chorionic gonadotropin for injection, USP) and ENDOMETRIN® (progesterone) Vaginal Insert for infertility. Ferring offers the Q?CAP(TM), the first needle-free reconstitution device, for use with its fertility treatments.
Other products include: ACTHREL® (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED® DS for the relief of discomfort of the lower urinary tract.
The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology, orthopaedics and infertility. For more information, call 888-337-7464 or visit http://www.FerringUSA.com/.
Source: Ferring Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.